- Home
- KYMR vs NGD Comparison
KYMR vs NGD Comparison
Compare KYMR & NGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- NGD
- Stock Information
- Founded
- KYMR 2015
- NGD N/A
- Country
- KYMR United States
- NGD Canada
- Employees
- KYMR N/A
- NGD N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- NGD
- Sector
- KYMR Health Care
- NGD
- Exchange
- KYMR Nasdaq
- NGD Nasdaq
- Market Cap
- KYMR 2.2B
- NGD 2.5B
- IPO Year
- KYMR 2020
- NGD 2004
- Fundamental
- Price
- KYMR $25.97
- NGD $3.64
- Analyst Decision
- KYMR Buy
- NGD Buy
- Analyst Count
- KYMR 13
- NGD 3
- Target Price
- KYMR $56.69
- NGD $3.88
- AVG Volume (30 Days)
- KYMR 847.3K
- NGD 23.2M
- Earning Date
- KYMR 05-01-2025
- NGD 04-29-2025
- Dividend Yield
- KYMR N/A
- NGD N/A
- EPS Growth
- KYMR N/A
- NGD N/A
- EPS
- KYMR N/A
- NGD 0.14
- Revenue
- KYMR $47,072,000.00
- NGD $924,500,000.00
- Revenue This Year
- KYMR $16.24
- NGD $25.37
- Revenue Next Year
- KYMR $22.41
- NGD $42.62
- P/E Ratio
- KYMR N/A
- NGD $28.15
- Revenue Growth
- KYMR N/A
- NGD 17.55
- 52 Week Low
- KYMR $19.45
- NGD $1.66
- 52 Week High
- KYMR $53.27
- NGD $3.86
- Technical
- Relative Strength Index (RSI)
- KYMR 44.70
- NGD 59.98
- Support Level
- KYMR $24.43
- NGD $3.46
- Resistance Level
- KYMR $26.06
- NGD $3.86
- Average True Range (ATR)
- KYMR 2.36
- NGD 0.24
- MACD
- KYMR 0.41
- NGD 0.02
- Stochastic Oscillator
- KYMR 70.12
- NGD 77.08
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.